Back to top
more

Abbott Laboratories (ABT)

(Delayed Data from NYSE)

$110.94 USD

110.94
7,458,602

+1.05 (0.96%)

Updated Aug 15, 2024 04:00 PM ET

After-Market: $110.95 +0.01 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 39% (99 out of 251)

Industry: Medical - Products

Better trading starts here.

Zacks News

Centene (CNC) Beats Q4 Earnings & Revenues, Ups '18 View

Centene's (CNC) fourth-quarter earnings were hurt by higher selling, general & administrative expenses.

    Anthem (ANTM) Tops Q4 Earnings & Revenues, Issues '18 View

    Anthem (ANTM) reported strong fourth-quarter results on the back of solid performance across its segments.

      HCA Healthcare's (HCA) Q4 Earnings, Revenues Beat Estimates (Revised)

      HCA Healthcare's (HCA) strong fourth-quarter results were driven by significant growth in admissions.

        MedTech Stock Q4 Earnings Slated for Jan 30: SYK, ZBH, ALGN

        The Medical sector is expected to stand out on favorable consumer behavior, growing prevalence of minimally-invasive surgeries, demand for liquid biopsy tests, and a value-based payment system.

          Boston Scientific's (BSX) Millipede Deal Aids MR Business

          Boston Scientific (BSX) claims the Millipede IRIS annuloplasty ring to be highly customizable to a specific patient's anatomy and disease state.

            Markets Keep Gaining Amid Strong Corporate Earnings

            Markets Keep Gaining Amid Strong Corporate Earnings

              Mark Vickery headshot

              Plethora of Q4 Earnings Amid New Market Highs

              From GE and Comcast to United Technologies and General Dynamics, the latest round of Q4 earnings results is accounted for.

                Abbott (ABT) Tops Q4 Earnings and Revenues, Issues Guidance

                Abbott (ABT) posts promising Q4 results on strong growth in all lines and expansion in emerging markets.

                  Abbott (ABT) Beats Earnings and Revenue Estimates in Q4

                  Abbott (ABT) rides high on new product approvals and launches in Q4.

                    Tracey Ryniec headshot

                    This Week's Amazing Earnings Charts

                    These 5 companies have consistently beat the earnings estimate. Will they do it again?

                      Can Diagnostics Business Drive Abbott's (ABT) Q4 Earnings?

                      Abbott (ABT) poised to gain on continued growth in Diagnostics business in Q4.

                        Can EPD & Medical Devices Drive Abbott's (ABT) Q4 Earnings?

                        Abbott (ABT) poised to ride high on continued growth in EPD and Medical Devices business in Q4.

                          Abbott's (ABT) Diabetes Care Unit Strong on FreeStyle Libre

                          Abbott (ABT) forges ahead with initiatives to boost diabetes care. The latest CMS recognition will widen customer base for FreeStyle Libre glucose monitoring system.

                            Abbott Boosts Diagnostics Arm With Alinity H-Series Launch

                            Abbott (ABT) adopts initiatives to strengthen hold in the high-potential diagnostics market.

                              The Zacks Analyst Blog Highlights: Pfizer, FedEx, Abbott, Biogen and Marathon Petroleum

                              The Zacks Analyst Blog Highlights: Pfizer, FedEx, Abbott, Biogen and Marathon Petroleum

                                Abbott (ABT) at a 52-Week High: What's Driving the Stock?

                                Abbott's (ABT) successful closure of the Alere acquisition after a prolonged legal battle has boosted investor confidence.

                                  Intersect ENT (XENT) SINUVA Implant Receives FDA Approval

                                  Intersect ENT's (XENT) consistent focus on the chronic sinusitis market is likely to lend the company a competitive edge in the niche space.

                                    Global In Vitro Diagnostic Market Booms: Stocks in Focus

                                    With the emergence of complex and transmittable diseases worldwide, In Vitro Diagnostic within the MedTech space is currently in the spotlight.

                                      DexCom-Lily Partnership to Boost CGM Platform, Customer Base

                                      DexCom (DXCM) continues to sign deals to boost CGM platform adoption.

                                        HCA Healthcare (HCA) Posts In-Line Q3 Earnings, Keeps View

                                        HCA Healthcare's (HCA) third quarter witnesses increase in revenues and admissions. However, expenses too escalate. The company reiterates guidance provided earlier this month.

                                          Abiomed (ABMD) Earnings and Revenues Beat Estimates in Q2

                                          Abiomed's (ABMD) strong performance in Impella heart pump boosted the company's second-quarter 2018 results.

                                            Integra LifeSciences (IART) Misses on Q3 Earnings & Revenues

                                            Integra LifeSciences' (IART) raised full-year 2017 revenue guidance buoys optimism.

                                              Align Technology (ALGN) Q3 Earnings Top on Invisalign Sales

                                              An extremely strong summer teen season drives Align Technology's (ALGN) Invisalign growth within the global teen market in the third quarter.

                                                Chemed (CHE) Beats on Q3 Earnings & Revenues, View Revised

                                                Chemed (CHE) rides high on its Roto-Rooter business in Q3

                                                  ResMed (RMD) Q1 Earnings Top on Growth in All Business Lines

                                                  ResMed (RMD) delivers a promising Q1 on the back of solid contributions from domestic and international businesses.